CClinicalTrials.gg
Status unknownNCT00566176RESTORE SR IIUpdated Feb 5, 2013

Sole-Therapy Treatment of Atrial Fibrillation

A Phase 2 interventional study of Surgical Ablation using the AtriCure Bipolar System in Atrial Fibrillation, sponsored by AtriCure, Inc.. Status unknown at 5 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2013-02-05.

Sponsored by AtriCure, Inc. · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Feb 2013), so the status shown — last known as Active, not recruiting — may be out of date.
Phase
Phase 2
Study type
Interventional
Enrollment
25
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

RESTORE SR II is a feasibility study on the minimally invasive use of the AtriCure Bipolar System for PV Isolation on a beating heart for the treatment of all types of atrial fibrillation in a sole therapy operation (not concomitant to another cardiac operation).

02

Conditions studied

  • Atrial Fibrillation

Browse trials for

Keywords

  • Atrial Fibrillation
  • AF
  • AFIB
  • racing heart
  • pulmonary vein isolation
  • pvi
  • mini maze
  • maze
03

In context

Atrial Fibrillation

3,869 studies on the registry are indexed under Atrial Fibrillation; 923 are open to participants now.

This study's enrollment of 25 is below the median of 144 across 2,380 interventional studies indexed under Atrial Fibrillation.

Browse Atrial Fibrillation studies →

Lead sponsor

AtriCure, Inc. is the lead sponsor of 31 studies on the registry; 5 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Male or female patient between 18 and 80 years of age
  2. Patient with symptomatic AF and failure or intolerance of one or more Class I or Class III AADs and:

    • Who describes 3 or more symptomatic AF episodes during the 6 month period prior to enrollment, with at least 1 electrocardiographically documented episode of AF in the 4 months prior to enrollment or,
    • Who has documented AF within the 6 months proceeding enrollment that did not terminate spontaneously (including patients in continuous AF) or,
    • Who is unwilling or unable to take anticoagulants, with 3 or more symptomatic episodes during the 6 month period prior to enrollment with at least 1 electrocardiographically documented episode of AF in the 4 months prior to enrollment.
  3. Left Atrial Size \< 6 cm (determined by echocardiography performed within 60 days of enrollment), unless the LV dysfunction is thought to result (at least in part) from AF
  4. Left Ventricular Ejection Fraction ≥ 30% (determined by echocardiography performed within 60 days of enrollment)
  5. Patient is willing and able to provide written informed consent.
  6. Patient has a life expectancy of at least 2 years.
  7. Patient is willing and able to attend the scheduled follow-up visits.
  8. Weight \< 325 lbs

Exclusion criteria

Exclusion Criteria:

  1. Prior cardiac catheter ablation for the treatment of arrhythmia within 4 months
  2. Prior cardiac surgery
  3. Patients requiring any open heart procedure (e.g. CABG, valve replacement or repair, atrial septal defect repair, etc.)
  4. Class IV NYHA heart failure symptoms, unless these symptoms are considered to be due to uncontrolled AF
  5. Cerebrovascular accident within previous 6 months
  6. Known carotid artery stenosis greater than 80%
  7. Evidence of significant active infection
  8. Patient unable to undergo TEE
  9. Pregnant woman
  10. Requires anti-arrhythmic drug therapy for the treatment of ventricular arrhythmia
  11. Presence of thrombus in the left atrium
  12. Patient has co-morbid condition that in the opinion of the investigator poses undue risk of general anesthesia or port access cardiac surgery
  13. Patient is enrolled in another investigational study
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (actual)

Interventions

  • DeviceSurgical Ablation using the AtriCure Bipolar System

    Surgical Ablation using the AtriCure Bipolar System

06

What researchers measure

Primary outcomes

  1. The primary outcome is the feasibility of performing this operation by demonstrating the ability to consistently isolate the right and left PVs using this minimally invasive approach.

    Time frame: Perioperatively

  2. The primary safety endpoint will be determined by assessing the rate of serious adverse events.

    Time frame: Discharge/30 Days

07

Study locations

5 sites
  • University Community Hospital/Dr. Kiran C. Patel Research Institute
    Tampa, Florida 33616, United States
  • University of Cincinnati
    Cincinnati, Ohio 45267, United States
  • University of Oklahoma Cardiac Arrythmia Research Institute
    Oklahoma City, Oklahoma 73104, United States
  • Sacred Heart Medical Center Endovascular Research
    Eugene, Oregon 97401, United States
  • Medical City Hospital/Cardio Pulmonary Research Science and Technology Institute
    Dallas, Texas 75230, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 5, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00566176
Lead sponsor
AtriCure, Inc.
Responsible party
Sponsor
First posted
Dec 3, 2007
Start date
Oct 2005
Primary completion
Dec 2007
Completion
Feb 2017 (estimated)
Last update
Feb 5, 2013

Study contacts

Warren Jackman, MD
principal investigator · University of Oklamhoma Cardiac Arrythmia Research Institute
James Edgerton, MD
principal investigator · Medical City Hospital/Cardio Pulmonary Research Science and Technology Institute
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion